Morgan Stanley Has Lowered Expectations for Envista (NYSE:NVST) Stock Price

Envista (NYSE:NVST) had its price target dropped by stock analysts at Morgan Stanley from $20.00 to $19.00 in a report issued on Thursday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 3.97% from the company’s previous close.

Several other research analysts have also commented on NVST. Piper Sandler raised their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Wells Fargo & Company upped their price objective on Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a report on Thursday. Mizuho initiated coverage on Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target on the stock. Finally, Jefferies Financial Group upped their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Envista currently has an average rating of “Hold” and an average price target of $20.13.

Envista Stock Down 1.9 %

Envista stock opened at $18.28 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The firm has a 50 day moving average price of $20.27 and a 200 day moving average price of $19.69. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The company has a market capitalization of $3.15 billion, a PE ratio of -2.82, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Research analysts expect that Envista will post 1 earnings per share for the current year.

Hedge Funds Weigh In On Envista

Several hedge funds have recently added to or reduced their stakes in NVST. Wealth Enhancement Advisory Services LLC grew its position in shares of Envista by 11.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,314 shares of the company’s stock valued at $303,000 after buying an additional 1,538 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Envista by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 19,887 shares of the company’s stock worth $392,000 after purchasing an additional 1,355 shares during the last quarter. US Bancorp DE increased its position in shares of Envista by 150.6% during the third quarter. US Bancorp DE now owns 4,971 shares of the company’s stock worth $98,000 after purchasing an additional 2,987 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Envista by 5.9% in the 3rd quarter. Assetmark Inc. now owns 38,641 shares of the company’s stock valued at $764,000 after purchasing an additional 2,152 shares during the last quarter. Finally, Covestor Ltd boosted its position in shares of Envista by 34.2% in the 3rd quarter. Covestor Ltd now owns 6,359 shares of the company’s stock valued at $125,000 after purchasing an additional 1,621 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.